Non-Hallucinogenic Psilocybin-Based Therapies Promote Neuroplasticity Show Promise Treating Mental Health Disorders with Joe Tucker Enveric Biosciences [Empowered Patient Podcast]
Monday, February 12, 2024 1 min read
Key Takeaway: Joe Tucker, CEO of Enveric Biosciences, highlights the potential of neuroplastogen therapies for treating neuropsychiatric disorders such as depression and PTSD. The company's Psybrary portfolio features compounds inspired by psilocybin that promote neuroplasticity without causing hallucinations. The lead candidate, EB-003, is designed for regular oral administration as a maintenance therapy.
Price reaction · baseline $138.6 (2024-02-12T14:30:00.000Z) · hit during market hours · clean, no other ENVB news in the window
day 0 close
+5.1%
day 1
+5.8%
day 3 · peak
+9.1%
Market Sentiment Analysis
POSITIVE FACTORS
Innovative approach to treating mental health disorders.
Non-hallucinogenic compounds may increase patient acceptance.
Potential for regular maintenance therapy with EB-003.
Full Press Release Details
Joe Tucker, CEO of Enveric Biosciences, discusses the use of neuroplastogen therapies for the treatment of neuropsychiatric disorders, including depression, anxiety, and post-traumatic stress disorder. Enveric has developed the Psybrary, a portfolio of compounds inspired by psilocybin that bind to the serotonin receptor in the brain and induce neuroplasticity without the hallucinations. The lead candidate EB-003 is intended to be administered orally and taken regularly as a maintenance therapy.
Full Article >>
Frequently Asked Questions
What is the focus of Enveric Biosciences?
Enveric Biosciences focuses on developing neuroplastogen therapies for neuropsychiatric disorders.
What is the lead candidate developed by Enveric?
The lead candidate is EB-003, designed for oral administration as a maintenance therapy.
How do these therapies work?
These therapies bind to serotonin receptors to promote neuroplasticity without inducing hallucinations.
What disorders are targeted by these therapies?
The therapies aim to treat depression, anxiety, and post-traumatic stress disorder.